NasdaqGS:IDXXMedical Equipment
Should Upward Analyst Earnings Revisions Prompt a Fresh Look at IDEXX Laboratories’ (IDXX) Growth Trajectory?
In recent days, IDEXX Laboratories has seen seven analysts revise their earnings estimates higher for fiscal 2025, with the Zacks Consensus Estimate for earnings per share now at US$12.55 and an average earnings surprise of 6.1% reported.
This momentum has positioned IDEXX as a favored growth stock among analysts, further supported by an A Momentum Style Score and consistently positive earnings revisions.
Given these upward analyst revisions and heightened optimism around future earnings,...